{"name":"Beijing Konruns Pharmaceutical Co., Ltd.","slug":"beijing-konruns-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"beijingkonruns.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"Jincaopian Tablets high dose","genericName":"Jincaopian Tablets high dose","slug":"jincaopian-tablets-high-dose","indication":"Other","status":"phase_2"},{"name":"KC1036","genericName":"KC1036","slug":"kc1036","indication":"Other","status":"phase_3"},{"name":"Kanitinib","genericName":"Kanitinib","slug":"kanitinib","indication":"Other","status":"phase_1"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Jincaopian Tablets","genericName":"Jincaopian Tablets","slug":"jincaopian-tablets","indication":"Respiratory conditions and immune support (specific indication under Phase 3 evaluation)","status":"phase_3"}]}],"pipeline":[{"name":"Jincaopian Tablets","genericName":"Jincaopian Tablets","slug":"jincaopian-tablets","phase":"phase_3","mechanism":"Jincaopian Tablets is a traditional Chinese medicine formulation that modulates immune function and inflammatory pathways to treat respiratory and immune-related conditions.","indications":["Respiratory conditions and immune support (specific indication under Phase 3 evaluation)"],"catalyst":""},{"name":"Jincaopian Tablets high dose","genericName":"Jincaopian Tablets high dose","slug":"jincaopian-tablets-high-dose","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"KC1036","genericName":"KC1036","slug":"kc1036","phase":"phase_3","mechanism":"KC1036 is a small molecule inhibitor targeting a specific kinase involved in cancer cell proliferation and survival.","indications":[],"catalyst":""},{"name":"Kanitinib","genericName":"Kanitinib","slug":"kanitinib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQeUR3VkU4aUNMSWU3QlFubEg4TXk1VWZTdVppTDFBVjRuenJ6VjNlWV9IVVpwVHpocTBtc01EaFNUSU1jVmJFSHhQNm1KQ3c2TGJMcGJFODlKemtZOEh0WUZkVUo4R004b1VTekc4YjlnaEF4a1A5TTg4a3ZyQTBHNDFPSkhWSmdrQzY1dy1jemlfejJmWWUwZEJEVUJMQQ?oc=5","date":"2026-02-20","type":"pipeline","source":"BioWorld News","summary":"Beijing Konruns Pharmaceutical discovers TACC inhibitors - BioWorld News","headline":"Beijing Konruns Pharmaceutical discovers TACC inhibitors","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":2,"phase_2":1,"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}